×
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.69 (-0.68%)
MSFT   262.20 (-1.02%)
META   168.86 (-0.37%)
GOOGL   2,285.89 (-1.33%)
AMZN   110.75 (-2.18%)
TSLA   728.29 (-0.88%)
NVDA   164.98 (-2.20%)
NIO   22.27 (-2.96%)
BABA   120.19 (+1.23%)
AMD   82.76 (-3.95%)
MU   59.45 (+1.14%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.23 (+0.78%)
F   12.22 (+1.50%)
DIS   99.89 (+3.40%)
AMC   13.61 (-3.68%)
PFE   51.37 (-0.98%)
PYPL   75.20 (-0.97%)
NFLX   186.30 (-1.50%)
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.69 (-0.68%)
MSFT   262.20 (-1.02%)
META   168.86 (-0.37%)
GOOGL   2,285.89 (-1.33%)
AMZN   110.75 (-2.18%)
TSLA   728.29 (-0.88%)
NVDA   164.98 (-2.20%)
NIO   22.27 (-2.96%)
BABA   120.19 (+1.23%)
AMD   82.76 (-3.95%)
MU   59.45 (+1.14%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.23 (+0.78%)
F   12.22 (+1.50%)
DIS   99.89 (+3.40%)
AMC   13.61 (-3.68%)
PFE   51.37 (-0.98%)
PYPL   75.20 (-0.97%)
NFLX   186.30 (-1.50%)
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.69 (-0.68%)
MSFT   262.20 (-1.02%)
META   168.86 (-0.37%)
GOOGL   2,285.89 (-1.33%)
AMZN   110.75 (-2.18%)
TSLA   728.29 (-0.88%)
NVDA   164.98 (-2.20%)
NIO   22.27 (-2.96%)
BABA   120.19 (+1.23%)
AMD   82.76 (-3.95%)
MU   59.45 (+1.14%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.23 (+0.78%)
F   12.22 (+1.50%)
DIS   99.89 (+3.40%)
AMC   13.61 (-3.68%)
PFE   51.37 (-0.98%)
PYPL   75.20 (-0.97%)
NFLX   186.30 (-1.50%)
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.69 (-0.68%)
MSFT   262.20 (-1.02%)
META   168.86 (-0.37%)
GOOGL   2,285.89 (-1.33%)
AMZN   110.75 (-2.18%)
TSLA   728.29 (-0.88%)
NVDA   164.98 (-2.20%)
NIO   22.27 (-2.96%)
BABA   120.19 (+1.23%)
AMD   82.76 (-3.95%)
MU   59.45 (+1.14%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.23 (+0.78%)
F   12.22 (+1.50%)
DIS   99.89 (+3.40%)
AMC   13.61 (-3.68%)
PFE   51.37 (-0.98%)
PYPL   75.20 (-0.97%)
NFLX   186.30 (-1.50%)
NASDAQ:PODD

Insulet Stock Forecast, Price & News

$230.64
+2.43 (+1.06%)
(As of 06/28/2022 10:58 AM ET)
Add
Compare
Today's Range
$226.29
$232.34
50-Day Range
$186.40
$273.21
52-Week Range
$181.00
$324.81
Volume
2,556 shs
Average Volume
439,938 shs
Market Capitalization
$15.99 billion
P/E Ratio
366.10
Dividend Yield
N/A
Price Target
$290.36
30 days | 90 days | 365 days | Advanced Chart

Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock Forecast (MarketRank)

Overall MarketRank

2.15 out of 5 stars

Medical Sector

426th out of 1,436 stocks

Surgical & Medical Instruments Industry

52nd out of 138 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
Insulet logo

About Insulet (NASDAQ:PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

PODD Stock News Headlines

Brokerages Set Insulet Co. (NASDAQ:PODD) PT at $290.17
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,300
Year Founded
2000

Company Calendar

Last Earnings
5/05/2022
Today
6/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$290.36
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$230.00
Forecasted Upside/Downside
+25.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.8
Research Coverage
10 Analysts

Profitability

Net Income
$16.80 million
Pretax Margin
4.33%

Debt

Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$1.09 per share
Book Value
$8.07 per share

Miscellaneous

Free Float
68,716,000
Market Cap
$15.99 billion
Optionable
Optionable
Beta
0.73

Social Links















Insulet Frequently Asked Questions

Should I buy or sell Insulet stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Insulet stock.
View analyst ratings for Insulet
or view top-rated stocks.

What is Insulet's stock price forecast for 2022?

10 Wall Street research analysts have issued twelve-month price objectives for Insulet's stock. Their PODD stock forecasts range from $230.00 to $350.00. On average, they anticipate Insulet's stock price to reach $290.36 in the next year. This suggests a possible upside of 26.0% from the stock's current price.
View analysts' price targets for Insulet
or view top-rated stocks among Wall Street analysts.

How has Insulet's stock performed in 2022?

Insulet's stock was trading at $266.07 at the beginning of the year. Since then, PODD stock has decreased by 13.4% and is now trading at $230.51.
View the best growth stocks for 2022 here
.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Insulet
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) issued its quarterly earnings results on Thursday, May, 5th. The medical instruments supplier reported $0.40 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.17. The medical instruments supplier earned $295.40 million during the quarter, compared to analyst estimates of $287.99 million. Insulet had a trailing twelve-month return on equity of 15.81% and a net margin of 3.91%. The company's revenue was up 17.1% on a year-over-year basis.
View Insulet's earnings history
.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its FY 2022 earnings guidance on Monday, May, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.23 billion-$1.27 billion, compared to the consensus revenue estimate of $1.24 billion.

Who are Insulet's key executives?

Insulet's management team includes the following people:

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by many different retail and institutional investors. Top institutional investors include Capital Research Global Investors (9.99%), Vanguard Group Inc. (8.95%), Capital World Investors (6.22%), Clearbridge Investments LLC (2.45%), Primecap Management Co. CA (1.78%) and Echo Street Capital Management LLC (1.16%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends for Insulet
.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Capital Research Global Investors, First Hawaiian Bank, Viking Global Investors LP, Sumitomo Mitsui Trust Holdings Inc., Bank of Nova Scotia, Frontier Capital Management Co. LLC, and Bank of New York Mellon Corp. Company insiders that have sold Insulet company stock in the last two years include Bret Christensen, Charles Alpuche, Eric Benjamin, John A Fallon, Sally Crawford, Shacey Petrovic, and Wayde D Mcmillan.
View insider buying and selling activity for Insulet
or view top insider-selling stocks.

Which institutional investors are buying Insulet stock?

PODD stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Clearbridge Investments LLC, Echo Street Capital Management LLC, Ownership Capital B.V., Renaissance Technologies LLC, Blair William & Co. IL, Jag Capital Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Insulet
or or view top insider-buying stocks.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $230.51.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $15.98 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.629990 on an earnings per share basis.

How many employees does Insulet have?

Insulet employs 2,300 workers across the globe.

When was Insulet founded?

Insulet was founded in 2000.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for Insulet is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at [email protected], or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.